£100m+ in PET-CT
Leading the
way in PET-CT
At Alliance Medical, we're making advanced PET-CT imaging accessible to hundreds of thousands of patients across the UK - helping detect diseases earlier and more accurately. As the National PET-CT Contract Holder for NHS England, we provide PET-CT scans to over 60% of the country, delivering fast, high-quality care when it’s needed. 91.3% of our patients are scanned within seven days and we’re proud to hold a 99% recommendation rate.
As leaders in molecular imaging, we operate over 34 PET-CT centres and 11 mobile units nationwide, scanning 12,000+ patients each month. In addition, we produce our own radiopharmaceuticals at five sites in the UK. Every day, we manufacture and supply a range of critical tracers, supporting a variety of indications across neurological, cardiac and oncological conditions. This dual expertise really sets us apart, delivering seamless diagnostics from start to finish.
National Contract Holder for NHS England
Over the past decade, Alliance Medical has been a pivotal player in supporting the NHS to expand its PET-CT network. We deliver NHS PET-CT services to 60% of England, lead the Molecular Imaging Collaborative Network and manufacture and distribute PET radiopharmaceuticals at 5 UK sites.
Investing in Digital PET-CT:
As a leader in molecular imaging, we are dedicated to improving diagnostic pathways. We are investing in our centres and our partnerships with NHS Trusts to deliver the very best service. This work has also seen us introduce multiple new digital PET-CT scanners across the UK. This innovative technology not only offers superior image quality but exposes patients to lower radiation.
It allows cancer to be detected at the very earliest stages, vastly improving treatment options and outcomes. This has been crucial in providing life-saving diagnostic imaging to hundreds of thousands of patients across England and reducing the cost burden on our healthcare system.
Specialist centres
Our specialist PET-CT centres with digital scanners include: Guildford, Sidcup, Leeds, Norwich, London, Oldham and Sheffield.
Types of tracers available:
FBB (Amyloid)
Also known as Florbetaben or 18F-florbetaben, FBB is primarily used to detect beta-amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. The presence and distribution of these plaques can help in the diagnosis and assessment of Alzheimer's and other neurodegenerative conditions.
FDG
The FDG tracer is one of the most used radiopharmaceuticals in PET-CT imaging and is primarily used to assess metabolic activity in tissues. It is widely employed in oncology for cancer detection, staging, and monitoring treatment response. Additionally, it is used in cardiology and neurology for evaluating heart conditions and brain disorders.
F-18 PSMA
18F-PSMA tracer is available at all of our PET-CT centres, helping to meet demand for detection of prostate cancer. A highly sensitive tracer, 18F-PSMA can detect very small prostate cancer lesions, allowing for earlier detection and more accurate staging, which is crucial for treatment planning.
Beyond Oncology
PET-CT is revolutionising the diagnosis and treatment of a range of indications beyond oncology, from brain and cardiac conditions, to autoimmune inflammatory diseases and paediatric care.
Our commitment extends from patient scans completed at our centres to supporting ground-breaking research into Alzheimer's and other neurological diseases. Our five radiopharmaceutical units ensure the production and distribution of vital PET radiopharmaceuticals across our network.
Our Community Diagnostic Centres
Alliance Medical created the UK's first Community Diagnostic Centre, and have delivered 9 innovative multimodality CDCs since. We are an award winning and trusted partner, currently working with over 100 partner NHS Trusts.
We're proud to provide state-of-the-art diagnostic facilities in the heart of the community, creating new patient pathways and improving access to MRI, CT and vitally PET-CT scanning. Our centre at Oldham has recently become the first CDC in the UK to have a static PET-CT.
Research and radiopharmacy
Alliance Medical is actively engaged in innovative research, including dementia trials and cancer studies.
With our ability to supply high quality isotopes, we make an important contribution to outcomes in research studies. In addition, we work with a number of affiliated organisations to bring new tracers to the market and improve patient pathways and outcomes.
We have five radiopharmaceutical production facilities across the UK and produce approximately c.170,000 doses per year. Find out more about our Radiopharmaceuticals.
